Journal Article Epublish
PubMed: 36293520 DOI: 10.3390/ijms232012664
Evaluating Thera-101 as a Low-Volume Resuscitation Fluid in a Model of Polytrauma.
Int J Mol Sci 23(20)
Authors: Jessica Stukel Shah, Joseph Macaitis, Bridney Lundquist, Brian Johnstone, Michael Coleman, Michelle A Jefferson, Jacob Glaser, Annette R Rodriguez, Sylvain Cardin, Heuy-Ching Wang, Alexander Burdette
Affiliations
- Naval Medical Research Unit San Antonio, Fort Sam Houston, San Antonio, TX 78234, USA.
- Theratome Bio, Inc. Indianapolis, IN 46202, USA.
- Air Force Research Laboratory, 711th Human Performance Wing, Airman Systems Directorate, Bioeffects Division, Veterinary Science Branch, San Antonio, TX 78234, USA.
Abstract
Traumatic brain injury (TBI) and hemorrhage remain challenging to treat in austere conditions. Developing a therapeutic to mitigate the associated pathophysiology is critical to meet this treatment gap, especially as these injuries and associated high mortality are possibly preventable. Here, Thera-101 (T-101) was evaluated as low-volume resuscitative fluid in a rat model of TBI and hemorrhage. The therapeutic, T-101, is uniquely situated as a TBI and hemorrhage intervention. It contains a cocktail of proteins and microvesicles from the secretome of adipose-derived mesenchymal stromal cells that can act on repair and regenerative mechanisms associated with poly-trauma. T-101 efficacy was determined at 4, 24, 48, and 72 h post-injury by evaluating blood chemistry, inflammatory chemo/cytokines, histology, and diffusion tensor imaging. Blood chemistry indicated that T-101 reduced the markers of liver damage to Sham levels while the levels remained elevated with the control (saline) resuscitative fluid. Histology supports the potential protective effects of T-101 on the kidneys. Diffusion tensor imaging showed that the injury caused the most damage to the corpus callosum and the fimbria. Immunohistochemistry suggests that T-101 may mitigate astrocyte activation at 72 h. Together, these data suggest that T-101 may serve as a potential field deployable low-volume resuscitation therapeutic.
MeSH
Multiple Trauma, Wounds And Injuries, Hemorrhage, Therapeutics, Resuscitation